Recent advances in managing and understanding enuresis by Van Herzeele, Charlotte et al.
 Open Peer Review
F1000 Faculty Reviews are commissioned
from members of the prestigious F1000
. In order to make these reviews asFaculty
comprehensive and accessible as possible,
peer review takes place before publication; the
referees are listed below, but their reports are
not formally published.
Discuss this article
 (0)Comments
REVIEW
 Recent advances in managing and understanding enuresis
[version 1; referees: 2 approved]
Charlotte Van Herzeele ,     Johan Vande Walle , Karlien Dhondt ,
Kristian Vinter Juul 3
Pediatrics, Department of Child Nephrology, Ghent University Hospital, Ghent, Belgium
Pediatrics, Department of Child Neurology & Metabolism, Pediatric Sleep Center, Ghent University Hospital, Ghent, Belgium
Ferring Pharmaceuticals, Copenhagen S, Denmark
Abstract
Enuresis, particularly in children during sleep, can be a debilitating condition,
affecting the quality of life of the child and his or her family. The
pathophysiology of nocturnal enuresis, though not clear, revolves around the
inter-related mechanisms of overactive bladder, excessive nocturnal urine
production, and sleep fragmentation. The first mechanism is more related to
isolated nocturnal voiding, whereas the latter two are more related to nocturnal
enuresis, in which circadian variations in arginine vasopressin hormone play a
key role. A successful treatment would depend upon appropriately addressing
the key factors precipitating nocturnal enuresis, necessitating an accurate
diagnosis. Thus, advancements in diagnostic tools and treatment options play
a key role in achieving overall success. This review summarizes recent
advances in understanding the pathophysiology of nocturnal enuresis,
diagnostic tools, and treatment options which can be explored in the future.
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Introduction
Enuresis is a cause of social, psychological, and emotional 
distress and carries a significant clinical burden1. It commonly 
refers to nocturnal enuresis (NE), which is defined as involuntary 
voiding during sleep, at least once a month, when patients have 
been symptomatic for a minimum of three months2. It may or 
may not be associated with other lower urinary tract symptoms 
(LUTSs) and thus can be classified as non-monosymptomatic 
NE (NMNE) or monosymptomatic NE (MNE), respectively. This 
leads to nights of disturbed sleep affecting a person’s quality of 
life (QoL), thus causing mood disturbance, daytime sleepiness, 
fatigue, and reduced work productivity3,4. Besides having impli-
cations for the patient, this condition can be stressful for the 
entire family5.
Though primarily reported in children with a prevalence of 
about 20% at five years of age, NE tends to affect about 2% of 
adults1. These data are often falsely interpreted as a high spon-
taneous resolution rate of NE, but in reality severe bed wetters 
(more than five wet nights per week) have only a 50% chance of 
achieving spontaneous resolution before adulthood, although for 
a mild to moderate condition, the prognosis may be more than 
90%. The association of NE with sleep pattern is still debatable; 
some researchers associate enuresis with “deep sleep” related to a 
high arousal threshold6 (although never evidence-based medicine- 
proven and largely subjective), whereas others correlate it with 
disturbed or “light sleep” with reduced feeling to wake up for 
voiding7. In fact, a recent study has shown a correlation between 
the two theories, concluding that children with NE have greater 
awakenings caused by bedwetting, which in turn causes sleep 
fragmentation (cortical arousal) and hence a high arousal 
threshold. So they fail to respond to a full bladder and this ends 
up in a vicious cycle of additional bedwetting8. Recently, newer 
data have attributed NE to periodic limb movement during sleep 
(PLMS)9, which we discuss later in this review.
It is also worthwhile to discuss the role of comorbidities associ-
ated with NE, which is partially understood. Although NE seems 
to be associated with psychological and behavioral comorbidities 
such as attention deficit hyperactivity disorder (ADHD), autism 
spectrum disorder, anxiety, depression, and constipation2,10, a 
definitive relationship has not yet been established and needs to 
be further evaluated in order to rationalize the need to appropri-
ately diagnose and manage the condition. Back in the nineties, 
Hägglöf et al.11 showed that self-esteem is reduced because of 
enuresis and it improves/normalizes when the child becomes 
dry. Moreover, studies have shown that NE might lead to comor-
bid conditions such as ADHD symptoms and PLMS12, besides 
causing sleep fragmentation8. From these two findings, it can be 
interpreted that sleep deprivation (for example, reducing it by 
one hour a night) might lead to reduced daytime functioning with 
the nightly PLMS and that these symptoms may disappear when 
dryness is achieved and sleep restored13. With these findings in 
view, it appears that enuresis and behavioral issues could have a 
cause-and-effect relationship, in which one might be stimulating 
the other, and it is difficult to say which stimulates what. Therefore, 
it is important to address the factors precipitating NE, which play 
a decisive role in treatment options. This review article therefore 
focuses on the recent advances in understanding the pathophysiol-
ogy of NE, its diagnosis, and treatment options.
Understanding the pathophysiology better
Over the years, our understanding of the pathophysiology of NE 
has advanced, making us realize that NE is far more complex than 
we understood three or four years ago. NE is generally associated 
with fragmented sleep, lower proportions of motionless sleep, and 
higher nighttime awakening8, although a recent finding suggests 
that NE is associated with PLMS. The periodic limb movement 
disorder (PLMD) consists of involuntary movements of the limbs, 
seen as a flexion in the knee, hip, or ankle, particularly during the 
non-rapid eye movement phase of sleep, when the person is 
unaware of such movements. It impacts the patient’s QoL, as it 
perturbs the sleep at night and may cause daytime sleepiness. A 
pediatric study showed that children with NE had significantly 
higher PLMS, arousal, and awakening indices during sleep than 
children in the control group, who had a sleep disorder with 
reasons other than NE9. The pathophysiology of PLMS is known 
to have its origin in dopaminergic neurotransmission14. Dopamine 
depletion results in reduced inhibition of spinal cord-induced motor 
and sensory reflexes, which are reflected by the presence of PLMS 
and an increase in sympathetic outflow. In the pontine region, 
dopamine also has an important role in the micturition center 
and inhibits bladder contractions. Consequently, hypodopaminer-
gic function results in reduced inhibition of spinal cord-induced 
muscle reflexes, which are reflected by the presence of PLMS 
and an increase of bladder contractions. Even though this is 
not completely understood, the co-occurrence of sleep fragmen-
tation, PLMS, and NE, at least in some phenotypes of NE, is 
remarkable. This suggests that, in these patients, dopamine, sleep 
fragmentation, and thereby an increased sympathetic activity and 
higher cardiac rate and blood pressure (BP) during the night15 
might play an interactive and important role.
Although the exact pathophysiology of NE remains partly under-
stood, the data available to date suggest that NE is possibly caused 
by three related mechanisms—nocturnal polyuria (NP), bladder 
overactivity, and sleep disorder16—which could be of urologi-
cal, neurological, genetic, or psychological origin17. Acetylcho-
line seems to play an important role in the pathophysiology of 
NE by increasing detrusor overactivity through its action on the 
M3 subtype of muscarinic acetylcholine receptors18. The bladder 
overactivity is seemingly more related to isolated nighttime void-
ing, whereas NP and sleep disorders are seemingly more related 
to NE. The pituitary hormone arginine vasopressin (AVP) plays 
a key role in the pathophysiology of NP and sleep disorders by 
regulating diuresis and sleep circadian rhythms, respectively19. 
As a result, a vicious cycle of sleep disruption and production 
of excessively large volumes of urine at night might lead to NE 
(Figure 1). Children may have a large urine production during 
some nights and not during other nights and that is reflected in 
their AVP profile. So whether or not AVP is going to be measured, 
one has to realize that the outcome is different from wet nights to 
dry nights. AVP normally has a fairly consistent circadian rhythm, 
especially in pre-pubertal children, but may extend up to later 
in life for some children. The wet nights may be particularly 
associated with a lack of normal rise in plasma AVP, especially in 
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Figure 1. Interplay between arginine vasopressin (AVP) and nocturnal enuresis (NE): understanding it better. (a) NE is caused by three 
related mechanisms: bladder overactivity (more related to isolated nighttime voiding), nocturnal polyuria (NP), and sleep disorders (more 
related to NE: AVP plays a key role by regulating diuresis and sleep circadian rhythms). (b) Copeptin, an attractive alternative biomarker for 
AVP measurement, which is released in equimolar quantities as AVP and has greater plasma stability compared with AVP. (c) Failure of the 
normal circadian rhythm of AVP in case of NE, resulting in large volumes of urine being produced at night. This led to the use of synthetic AVP 
analogue “desmopressin” as a treatment option.
the first part of the night20. According to a theory that has recently 
surfaced, AVP circadian rhythms are not exclusively responsible 
for NP and in fact there are other intrinsic renal circadian systems 
that might be involved in the pathophysiology of NE21.
Non-dipping BP during the night is another factor which leads 
to NE. Healthy individuals experience a nearly 10% decline in 
nocturnal arterial BP versus daytime arterial BP. In a study con-
ducted in 45 children with MNE, dipping in systolic and diastolic 
BP based on a change of “<10%” was found to be significantly 
higher in patients than in healthy controls (n = 22; P <0.05)22. 
Although the mechanism of these circadian changes in BP is not 
well understood, it might be a target of future NE treatment to 
enhance the BP dipping.
Advancements in diagnosis
The initial diagnosis of NE is based on the subjective infor-
mation provided by the patient or caregiver followed by self-
filled diary data, which evaluate functional bladder volume and 
nocturnal diuresis23. Most of the pediatric patients and their 
parents understand the importance of this crucial diagnostic tool, 
for which the validity is already established. However, these 
methods are sometimes inaccurate/biased and can lead to 
inappropriate diagnosis and treatment. In this scenario, it seems 
imperative to measure the plasma levels of AVP, not only for 
diagnosis but also for making treatment-related decisions and 
prognosis. However, measuring AVP accurately is practically chal-
lenging because of the unstable nature of the molecule and very 
short plasma half-life (about 20 minutes)24. Also, more than 90% 
of the AVP is bound to platelets, precluding its accurate estimation. 
An attractive alternative in this regard could be a biomarker that 
is stable and easy to measure in laboratories even with basic 
infrastructure.
In this regard, copeptin, a cleavage product of peptide pre- 
pro-AVP during AVP synthesis, is being explored. The precur-
sor peptide pre-pro-AVP is enzymatically cleaved into three 
components—vasopressin, copeptin, and neurophysin II—all 
released in equal proportions in the blood circulation. Recent 
advancements in biomarker research have delineated the use 
of copeptin as a surrogate marker for AVP measurements 
(Figure 1)25.
Copeptin (also known as CTproAVP), a 39-amino-acid glyco-
peptide, is the C-terminal part of the precursor peptide. Its level 
mirrors the levels of AVP in the body and changes with change 
in osmolarity. Compared with AVP, copeptin is much more sta-
ble in plasma (in vitro) and during storage, does not require any 
pre-analytical processing and can be determined by using man-
ual and automated assays25. Moreover, copeptin concentration is 
independent of age26, lacks consistent circadian rhythms27 (unlike 
AVP, as discussed above), increases post-workout, and is higher in 
men than in women28.
The role of copeptin as an important biomarker is already 
established and validated in various conditions where AVP plays 
a role. A recent study has shown its utility to differentiate central 
diabetes insipidus (DI) from nephrogenic DI. The former is 
caused by impaired AVP production/secretion from the posterior 
pituitary, and the latter is due to decreased sensitivity of the 
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kidneys to AVP29. Consequently, copeptin appears to be a prom-
ising new diagnostic biomarker to discriminate between different 
entities of polydipsia-polyuria condition, which consists of 
central DI, nephrogenic DI, and primary polydipsia. This 
differentiation is important, since inadequate treatment can lead 
to serious complications such as hyponatremia30. Even in patients 
with autosomal dominant polycystic kidney disease, marked by 
high AVP levels, measuring copeptin levels can help to predict 
disease progression and severity31–33. In all of the above disease 
conditions, copeptin levels are seen to be directly correlated 
with AVP levels; however, the reverse is true in the case of 
chronic kidney disease (CKD). This is due to partial clearance of 
copeptin by the kidneys, hence increasing its plasma level in 
patients with CKD compared with those with preserved kidney 
function34,35. Copeptin also helps in the prognosis of CKD, as 
increasing copeptin levels predict a decline in estimated glomerular 
filtration rate36.
Given the benefits of copeptin as a diagnostic and prognostic 
marker for AVP deficiency, it is now being explored for its 
diagnostic value in NE. However, until now, only one study has 
attempted to assess the relationship between copeptin and NE. 
This pediatric study (n = 88) showed that copeptin levels were 
significantly lower in patients with NE versus healthy controls. 
Within NE as well, copeptin levels were significantly lower 
in severe bed wetters (at least two nights per week) versus less- 
severe bed wetters (not more than one night per week). In the 
same study, however, AVP levels were not significantly different 
between any of the groups37. This suggests that, compared with 
AVP, copeptin has a higher sensitivity in differentiating between 
the severity of NE and also better represents the low levels of 
AVP. This could be attributed to lower stability of AVP and also 
to the fact that a large fraction of AVP exists as platelet-bound as 
compared with copeptin.
So, if copeptin is going to have a role in the diagnosis of NE or 
even a role in the study of its pathophysiology, then a lot of 
studies lie ahead. Therefore, there is an emergent need to explore 
the utility of copeptin in establishing the diagnosis of NE due to 
NP and sleep disorders and in differentiating it from NE due to 
bladder overactivity. Once the diagnosis is established accurately, 
it will help physicians make better treatment-related decisions. 
Currently available treatments and recent advancements in this 
field are discussed in the following section.
Newer therapeutic modalities
NE often remains un- or under-treated, primarily because of 
inappropriate or inadequate diagnosis despite the guidelines and 
recommendations in place. Treatment ideally should begin in 
children older than five years and in adults as soon as the 
condition is diagnosed.
An optimum treatment for NE would be the one that is based on 
a precise diagnosis and addresses the key underlying factor driv-
ing the disease pathophysiology. The recent consensus guidelines 
of the International Children’s Continence Society recommend 
education and motivational therapy to the child/parent/caregiver 
and behavioral advice to the child (diet/fluid restriction at night, 
voiding before going to bed) as the first-line treatment. In case of 
no respite, it is recommended to differentiate LUTS-associated 
NMNE from MNE, which is based on the voiding diary completed 
by the child/parent/caregiver, and once the diagnosis is ascertained, 
the treatment decision can be made. If the patient is diagnosed 
with MNE, the second-line treatment should preferably consist 
of a synthetic AVP analog—desmopressin (in case of NP only)—
and an enuretic alarm (in case of reduced bladder capacity only). 
Moreover, a combination of desmopressin and alarm can be used 
in patients with both NP and reduced bladder capacity or when 
children using alarm therapy wake up more than once during the 
night23. However, a minority of children with MNE are resistant 
to the standard treatment of either desmopressin or alarm therapy. 
Since in desmopressin-resistant patients, one of the mechanisms 
for enuresis seems to be excessive prostaglandin production at 
night, non-steroidal anti-inflammatory drugs (NSAIDs) such as 
indomethacin are suggested as a therapeutic alternative38. Apart 
from NSAIDs, tricyclic antidepressants such as imipramine have 
come up as a useful alternate option, acting partly by reducing 
the clearance of solutes and partly by increasing urea and water 
reabsorption from the kidneys39. Although imipramine proves 
to be cardiotoxic when overdosed, thus limiting its use in this 
condition, newer antidepressant options such as reboxetine have 
shown benefit. A recent placebo-controlled study in which enuretic 
children were given reboxetine 4 mg as monotherapy and as 
combination with desmopressin showed significant reduction in 
wet nights versus placebo (P = 0.002)40.
In case of NMNE, it is recommended to treat the comorbidi-
ties before initiating enuresis treatment, which could consist of 
a combination of desmopressin and anticholinergics (for example, 
oxybutynin). This combination can also be useful in MNE patients 
who fail to respond to alarm and desmopressin combination 
therapy41. Thus, it is clear that owing to the complex pathophysi-
ology that varies among patients, one treatment option may not 
suit them all.
Desmopressin has long been the treatment of choice for NE, and 
the following recent studies support this claim. In a prospective 
study involving MNE children, desmopressin has shown imme-
diate and long-term effects that are as great as those of alarm 
therapy or a combination of alarm and desmopressin42. Another 
prospective open-label study in a similar patient population given 
desmopressin has shown an improvement in sleep pattern post-
therapy by a significant decrease in PLMS index (P <0.001) at 
six months from baseline and prolonged first undisturbed sleep 
period (or time to first nocturnal void; P <0.001). This is also 
the first study to confirm the relationship among enuresis, 
neuropsychological dysfunction, and sleep disorders in an MNE 
population42. Desmopressin also seems to be an effective treat-
ment option for NE in patients undergoing orthotopic neobladder 
reconstruction after radical cystectomy, where it significantly 
reduced the mean number of nocturnal voids (P = 0.015). Also, the 
number of patients with not more than one episode of NE per week 
increased from 19% to 39% after taking desmopressin. In 42% of 
patients, there was an increase of a minimum of one to two hours 
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of sleep until the first nocturnal void, thus improving sleep quality 
and QoL43.
Although desmopressin has been the standard treatment for 
MNE, there are still 20 to 60% of children who do not respond to 
the treatment and are desmopressin-resistant. These patients have 
a low bladder volume and low diuresis volume with high urinary 
osmolality overnight. In contrast, the desmopressin-responding 
patients have large bladder volume and high diuresis volume with 
low urinary osmolality overnight. Thus, a voiding diary can defi-
nitely help to individualize therapy44. Desmopressin resistance 
in patients often coincides with the presence of comorbidities 
(constipation, attention problems, sleep disorders, and mental and 
motoric disability), thus making it essential to treat them first if 
possible. The pathophysiology for NE in these patients might 
involve renal circadian rhythms other than that of AVP21. This has 
enhanced the need for alternative treatment options, particularly in 
the less well-defined MNE, where apparently a significant number 
of patients with NMNE are included.
Recently, transcutaneous electrical neural stimulation therapy 
(TENS), which is an established treatment option for hyperac-
tive bladder and NMNE, has shown benefits in managing MNE 
as well. In the latter group versus controls, this therapy signifi-
cantly reduced the rate of wet nights (P = 0.02) and increased the 
rate of dry nights (P = 0.004) regardless of age or gender45. 
Long-term urodynamic studies have shown that there is no 
change in bladder activity, so it seems that the effect can be attrib-
uted to coping. Even though TENS has shown some benefits in 
patients with MNE, future studies need to be carried out in order to 
explore this treatment option.
Biomarker for treatment effectiveness
Although desmopressin is the recommended treatment option 
for MNE, a biomarker to predict drug effectiveness is manda-
tory. Recently, urinary aquaporin 2, the major urine concentra-
tion factor, has come up as a biomarker of desmopressin treatment 
effectiveness during therapy. This pediatric study in which 
patients were treated with 120 or 240 μg desmopressin orally 
disintegrating tablets was divided into responders and non- 
responders. After eight weeks of treatment, a significant correla-
tion was observed between day/night ratio of aquaporin 2 and 
percentage of wet nights. In the responder group, there was a 
significant difference in the change in aquaporin 2 day/night 
ratio from before treatment to complete remission (P = 0.0004)46.
Conclusions
Nocturnal enuresis in children as well as adults can be detrimen-
tal for their overall development and well-being. Although the 
pathophysiology is unclear, NE is associated with a high arousal 
threshold and fragmented sleep, often associated with PLMD. 
Appropriate diagnosis for the reason precipitating NE is essen-
tial in order to provide the right treatment option. Copeptin seems 
to be a promising biomarker for AVP measurement, and more 
studies are needed in the future to establish the cause of NE. 
Desmopressin is the recommended treatment option for MNE 
associated with NP, but in a few patients who are treatment- 
resistant, newer options need to be investigated. In summary, 
this review article addresses new possible avenues and illustrates 
that there is so much to do in the future. The major achievement 
during the last few decades is that children are taken seriously 
and that it is realized that enuresis is not just enuresis but a lot of 
different entities.
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